Phibro Animal Health Corporation (PAHC)
USD 19.48
(4.73%)
USD 19.48
(4.73%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 525.45 Million USD | 3.04% |
| 2023 | 509.96 Million USD | 8.39% |
| 2022 | 470.48 Million USD | 10.26% |
| 2021 | 426.7 Million USD | 3.89% |
| 2020 | 410.72 Million USD | 25.92% |
| 2019 | 326.17 Million USD | 4.42% |
| 2018 | 312.38 Million USD | -0.24% |
| 2017 | 313.14 Million USD | -11.22% |
| 2016 | 352.71 Million USD | 21.83% |
| 2015 | 289.51 Million USD | 0.04% |
| 2014 | 289.39 Million USD | -20.85% |
| 2013 | 365.6 Million USD | 4.42% |
| 2012 | 350.12 Million USD | 0.0% |
| 2007 | 240.6 Million USD | 10.22% |
| 2006 | 218.3 Million USD | 18.19% |
| 2005 | 184.7 Million USD | 8.71% |
| 2004 | 169.9 Million USD | 19.73% |
| 2003 | 141.9 Million USD | -23.67% |
| 2002 | 185.9 Million USD | 7.96% |
| 2001 | 172.2 Million USD | 14.42% |
| 2000 | 150.5 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 513.09 Million USD | -1.01% |
| 2024 FY | 525.45 Million USD | 3.04% |
| 2024 Q3 | 522.98 Million USD | 1.93% |
| 2024 Q4 | 525.45 Million USD | 0.47% |
| 2024 Q1 | 518.34 Million USD | 1.64% |
| 2023 Q3 | 517.71 Million USD | 1.17% |
| 2023 Q1 | 503.11 Million USD | 6.94% |
| 2023 FY | 509.96 Million USD | 8.39% |
| 2023 Q4 | 509.96 Million USD | -1.5% |
| 2023 Q2 | 511.74 Million USD | 1.71% |
| 2022 FY | 470.48 Million USD | 10.26% |
| 2022 Q3 | 455.68 Million USD | 4.82% |
| 2022 Q4 | 470.48 Million USD | 3.25% |
| 2022 Q1 | 438.82 Million USD | 2.84% |
| 2022 Q2 | 434.73 Million USD | -0.93% |
| 2021 Q3 | 413.58 Million USD | 0.64% |
| 2021 Q4 | 426.7 Million USD | 3.17% |
| 2021 Q2 | 410.96 Million USD | -2.44% |
| 2021 FY | 426.7 Million USD | 3.89% |
| 2021 Q1 | 421.24 Million USD | 2.56% |
| 2020 FY | 410.72 Million USD | 25.92% |
| 2020 Q1 | 416.93 Million USD | 27.83% |
| 2020 Q3 | 389.81 Million USD | -1.86% |
| 2020 Q4 | 410.72 Million USD | 5.36% |
| 2020 Q2 | 397.19 Million USD | -4.73% |
| 2019 Q2 | 324.27 Million USD | -0.02% |
| 2019 Q3 | 329.22 Million USD | 1.53% |
| 2019 Q4 | 326.17 Million USD | -0.93% |
| 2019 FY | 326.17 Million USD | 4.42% |
| 2019 Q1 | 324.33 Million USD | 3.83% |
| 2018 Q1 | 331.85 Million USD | 5.98% |
| 2018 Q3 | 309.37 Million USD | -2.21% |
| 2018 Q4 | 312.38 Million USD | 0.97% |
| 2018 FY | 312.38 Million USD | -0.24% |
| 2018 Q2 | 316.36 Million USD | -4.67% |
| 2017 Q3 | 309.46 Million USD | -5.8% |
| 2017 Q4 | 313.14 Million USD | 1.19% |
| 2017 FY | 313.14 Million USD | -11.22% |
| 2017 Q1 | 342.6 Million USD | -2.87% |
| 2017 Q2 | 328.53 Million USD | -4.11% |
| 2016 Q4 | 352.71 Million USD | -3.74% |
| 2016 Q3 | 366.41 Million USD | 20.09% |
| 2016 Q1 | 306.32 Million USD | 5.81% |
| 2016 Q2 | 305.12 Million USD | -0.39% |
| 2016 FY | 352.71 Million USD | 21.83% |
| 2015 Q3 | 287.22 Million USD | -0.25% |
| 2015 FY | 289.51 Million USD | 0.04% |
| 2015 Q4 | 289.51 Million USD | 0.8% |
| 2015 Q2 | 287.94 Million USD | -0.25% |
| 2015 Q1 | 288.66 Million USD | -0.25% |
| 2014 Q4 | 289.39 Million USD | -22.72% |
| 2014 Q1 | 379.7 Million USD | 3.86% |
| 2014 FY | 289.39 Million USD | -20.85% |
| 2014 Q2 | 363.82 Million USD | -4.18% |
| 2014 Q3 | 374.46 Million USD | 2.93% |
| 2013 Q4 | 365.6 Million USD | 0.0% |
| 2013 FY | 365.6 Million USD | 4.42% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 350.12 Million USD | 0.0% |
| 2007 FY | 240.6 Million USD | 10.22% |
| 2006 Q3 | 176.7 Million USD | -1.94% |
| 2006 FY | 218.3 Million USD | 18.19% |
| 2006 Q1 | 181.1 Million USD | -1.95% |
| 2006 Q2 | 180.2 Million USD | -0.5% |
| 2005 Q2 | 180.7 Million USD | 6.36% |
| 2005 Q1 | 169.9 Million USD | 0.0% |
| 2005 FY | 184.7 Million USD | 8.71% |
| 2005 Q4 | 184.7 Million USD | 0.71% |
| 2005 Q3 | 183.4 Million USD | 1.49% |
| 2004 Q1 | 144.1 Million USD | 1.55% |
| 2004 Q4 | 169.9 Million USD | -1.56% |
| 2004 Q3 | 172.6 Million USD | 1.89% |
| 2004 FY | 169.9 Million USD | 19.73% |
| 2004 Q2 | 169.4 Million USD | 17.56% |
| 2003 Q2 | 169 Million USD | 1.14% |
| 2003 Q1 | 167.1 Million USD | 0.0% |
| 2003 FY | 141.9 Million USD | -23.67% |
| 2003 Q4 | 141.9 Million USD | -0.7% |
| 2003 Q3 | 142.9 Million USD | -15.44% |
| 2002 FY | 185.9 Million USD | 7.96% |
| 2001 FY | 172.2 Million USD | 14.42% |
| 2000 FY | 150.5 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 2.863% |
| Theratechnologies Inc. | 58.96 Million USD | -791.092% |
| Safety Shot Inc | 1.54 Million USD | -33823.035% |
| Cosmos Health Inc. | 12.42 Million USD | -4129.403% |
| Cronos Group Inc. | 2.53 Million USD | -20587.867% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 26.564% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -1346.629% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -340.264% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -9484.372% |
| ProPhase Labs, Inc. | 21.38 Million USD | -2357.713% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -86324.177% |
| Dynavax Technologies Corporation | 256.91 Million USD | -104.527% |
| Radius Health, Inc. | 365.31 Million USD | -43.838% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -19747.703% |
| Alvotech | 1.07 Billion USD | 51.142% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -79792.809% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1625.192% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -3002.249% |
| SCYNEXIS, Inc. | 15.08 Million USD | -3384.476% |
| Harrow Health, Inc. | 190.5 Million USD | -175.829% |
| Biofrontera Inc. | 5.39 Million USD | -9632.525% |
| DURECT Corporation | 20.74 Million USD | -2432.821% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1165.343% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -66.639% |
| OptiNose, Inc. | 131.74 Million USD | -298.833% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -44695.934% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -431.723% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -2751.342% |
| SIGA Technologies, Inc. | 1.46 Million USD | -35791.787% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -303.083% |
| Shineco, Inc. | 29.65 Million USD | -1671.821% |
| Procaps Group S.A. | 285.93 Million USD | -83.769% |
| TherapeuticsMD, Inc. | 8 Million USD | -6464.135% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -878491.133% |
| Viatris Inc. | 18.12 Billion USD | 97.101% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -79792.809% |
| Rockwell Medical, Inc. | 13.43 Million USD | -3809.956% |
| Incannex Healthcare Limited | 373 Thousand USD | -140773.726% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -3373.191% |
| Tilray Brands, Inc. | 387.31 Million USD | -35.666% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 22.071% |
| PetIQ, Inc. | 468.3 Million USD | -12.205% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -22.656% |
| Journey Medical Corporation | 17.73 Million USD | -2863.672% |
| Alimera Sciences, Inc. | 67.39 Million USD | -679.624% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -6248.737% |
| Assertio Holdings, Inc. | 40.91 Million USD | -1184.364% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -48209.451% |
| Embecta Corp. | 1.63 Billion USD | 67.93% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -50761.617% |
| Procaps Group, S.A. | 285.93 Million USD | -83.769% |
| PainReform Ltd. | 86 Thousand USD | -610898.836% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -1385.019% |
| Hempacco Co., Inc. | 13.72 Million USD | -3728.619% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 10.338% |
| Alvotech | 1.07 Billion USD | 51.142% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 14.829% |
| Kamada Ltd. | 8.74 Million USD | -5905.941% |
| Indivior PLC | 281.6 Million USD | -86.596% |
| Currenc Group, Inc. | 31.94 Million USD | -1544.957% |
| Evoke Pharma, Inc. | 5 Million USD | -10409.18% |
| Flora Growth Corp. | 3.67 Million USD | -14209.886% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -50761.617% |
| Evolus, Inc. | 126.54 Million USD | -315.232% |
| HUTCHMED (China) Limited | 86.13 Million USD | -510.07% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 15.743% |
| Akanda Corp. | 3.99 Million USD | -13040.447% |